FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compounds of general formula (I): 
where R1, R3 and R4 represent H; R2 represents halogen; each R5 and R6 independently represents H, C1-C6 alkyl R7 represents H, C1-C6 alkyl; R8 represents phenyl, naphthalinyl, thiazolyl, biphenyl, quinolinyl or quinoxalinyl, each of which can contain one or several substituents, selected from group, including halogen, C1-C6 alkyl, -O-(C1-C6 alkyl), C1-C6 halogenalkyl, -O- C1-C6 halogenalkyl, -SO2R11 or -OH; each R11 represents independently H, C1-C6 alkyl; on condition that R8 does not represent unsubstituted phenyl; R9 represents H, C1-C6 alkyl; or its pharmaceutically acceptable salt.
EFFECT: compounds I possess antagonistic activity with respect to PGD2 for receptor CRTH2, which makes it possible to use them in pharmaceutical composition used in treatment of a number of diseases.
27 cl, 3 tbl, 1 dwg, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | 2009 |
|
RU2503672C2 |
| NOVEL SUBSTITUTED INDOLES | 2003 |
|
RU2288914C2 |
| COMPOUNDS SHOWING CRTH2 ANTAGONIST ACTIVITY | 2007 |
|
RU2458918C2 |
| 2,3-SUBSTITUTED PYRAZINE SULPHONAMIDES AS CRTH2 INHIBITORS | 2006 |
|
RU2453540C2 |
| POLYMORPHIC FORM OF [5-FLUORINE-3-({ 2-[(4-FLUOROBENZENE) SULFONYL]PYRIDINE-3-YL} METHYL)-2-METHYLINDOLE-1-YL]-ACETIC ACID | 2015 |
|
RU2751319C2 |
| HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | 2008 |
|
RU2451019C2 |
| POLYMORPHOUS FORM OF [5-FLUORO-3-({2-[(4-FLUOROBENZENE) SULPHONYL]PYRIDIN-3-YL}METHYL)-2-METHYLINDOLE-1-YL]-ACETIC ACID | 2015 |
|
RU2702343C2 |
| BIPHENYLOXYACETIC ACID DERIVATIVES, USE THEREOF IN PREPARING MEDICINAL AGENT AND INTERMEDIATE COMPOUNDS | 2006 |
|
RU2424229C2 |
| DERIVATIVES OF IMIDAZO[1,2-C]PYRIMIDINYL ACETIC ACID | 2005 |
|
RU2373208C2 |
| COMPOUNDS AND COMPOSITIONS AS TRO MIMETICS | 2006 |
|
RU2385865C2 |
